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Open access under CC BYThe requirement to cross a biological membrane can be a complex process especially if multidrug trans-
porters such as P-gp must be considered. Drug partitioning into the lipid membrane and efﬂux by P-gp
are tightly coupled processes wherein H-bonding interactions play a key role. All H-bond donors and
acceptors are not equal in terms of the strength of the H-bonds that they form, hence it is important
to consider their relative strength. Using various examples from literature, we illustrate the beneﬁts of
considering the relative strengths of individual H-bonds and introducing intramolecular H-bonds to
increase membrane permeability and/or decrease P-gp efﬂux.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.During preclinical development, medicinal chemists design
compounds for effective delivery to the appropriate tissue or site
of action. This requires, in many instances, crossing a lipid mem-
brane or cellular barrier. Therefore, the compounds need to have
the appropriate balance of physiochemical properties to cross
these barriers preferably by passive diffusion. In addition, there
are active efﬂux transporters located in these membranes whose
goal is to ‘pump out’ xenobiotics or potentially toxic substances
including drugs, which can negatively impact attaining target
engagement at a desired dose. Consequently, structure–activity
relationships (SAR) that improve biological activity and maintain
appropriate physicochemical properties to provide an acceptable
pharmacokinetic proﬁle can be a daunting task for the medicinal
chemist.
The human ATP-binding cassette (ABC) transporters belong to a
superfamily of 51 human genes classiﬁed into seven subfamilies.1
These transporters use the energy of ATP hydrolysis to extrude com-
pounds across a lipid membrane by a complex translocation pro-
cess.2 Nine of these proteins are involved in multi-drug transport.
The most studied transporters are ABCB1, better known as P-glyco-
protein (P-gp) or MDR1, ABCG2, known as breast cancer resistance
protein (BCRP), and several multidrug resistance-associated pro-
teins (MRPs) from the ABCC subfamily comprised of 13 proteins.3
Of all the known efﬂux pumps, P-gp is the one most widely studied: +1 317 433 0541.
co).
-NC-ND license.and understood.4 Because P-gp is localized at the surface of endo-
thelial or epithelial cells, it can pump drugs back to the external
space or to the blood depending upon the orientation of expression
(Fig. 1), which can affect absorption, distribution, and elimination of
substrates. Therefore, knowledge of successful SAR strategies to
circumvent, or conversely to introduce P-gp efﬂux if CNS exposure
might need to be reduced, could be valuable learning for the medic-
inal chemist. For example, a decrease in unbound CNS exposure
might be achieved such that a sufﬁcient margin of safety is realized
against an unwanted CNS side effect as suggested by Polli et al. for
differentiating sedating (P-gp substrates) from non-sedating
(non-P-gp substrates) antihistamines.5 A similar differentiation
was proposed recently to explain the CNS-sparing, clinical outcome
of antimuscarinic agents that are P-gp substrates.6
In the last few years, the medicinal chemistry ﬁeld has seen a
tremendous initiative to link successful marketed drugs to drug-
like attributes and speciﬁc physicochemical properties with the
ultimate goal of improved medicinal chemistry design.7,8 In the
CNS area, retrospective analysis of marketed drugs has shown that
P-gp efﬂux and passive permeability are two crucial parameters to
evaluate.9,10 Recently, Wager et al. highlighted a set of six physico-
chemical properties, for example, c logP (calculated logarithm of
the octanol/water partition coefﬁcient), c logD (calculated loga-
rithm of the octanol/water distribution coefﬁcient at pH 7.4),
molecular weight (MW), topological Polar Surface Area (TPSA),
number of hydrogen bond (H-bond) donors (HBD; NH and OH
groups), and most basic center (pKa, logarithm of the acid dissoci-
ation constant), as the most relevant descriptors to take into
Figure 1. Schematic representation of P-gp expression and direction of net transport at different cellular barriers.
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efﬂux and permeability.8,11 These molecular descriptors are readily
predicted with reasonable accuracy to guide SAR design. Interest-
ingly and contrary to popular understanding based on the total
brain-to-plasma concentration ratio, hydrophobicity does not ap-
pear to be a dominant determining factor of unbound brain expo-
sure. The molecular descriptors related to polarity such as H-bond
acceptors (HBA; N and O atoms), HBD and TPSA have been reported
by many to be key factors for CNS exposure and especially deter-
mining unbound brain exposure.8,12 The additive effect of increas-
ing TPSA (through increase in HBA/HBD count) on decreasing
passive permeability and simultaneously increasing P-gp transport
efﬁciency, is likely to be responsible for a decrease in free drug
exposure in brain.13
In our analysis of unbound brain exposure at ﬁve minutes after
an intravenous bolus dose in mice14 for a set of approximately
1000 structurally-diverse compounds from the Eli Lilly collection,
it appeared that compounds with c logP less than 4.0 and with TPSA
between 40–80 Å2 had greater propensity to achieve relatively
higher unbound brain exposure. In another internal analysis of
2000 compounds tested for P-gp efﬂux using bidirectional ﬂux
across MDCK-MDR1 cell monolayers, we observed that compounds
with TPSA less than 60 Å2 and a calculated most basic pka of less
than 8.0 had a much higher likelihood of being identiﬁed as non-
P-gp substrates (94%) (unpublished data). Similar P-gp non-sub-
strate behavior was observed if we replaced TPSA with HBA counts
of less than 7. This was not surprising since TPSA is mainly depen-
dent upon the total number of oxygen and nitrogen atoms. We also
observed that increasing passive permeability is aligned with rela-
tively lower likelihood of identifying a compound as a P-gp sub-
strate in vitro. Because P-gp most likely binds its substrates in the
lipid membrane, speciﬁcally in the cytosolic membrane leaﬂet,
and then ﬂips them to the outer leaﬂet, compounds must ﬁrst cross
the membrane by passive diffusion to reach the P-gp binding site.15
If a compound diffuses rapidly across the membrane it can partially
escape to the cytosol before being ‘caught’ by P-gp. Thus, P-gp efﬂux
transport efﬁciency might be decreased by increasing passive per-
meability and could be one possible strategy for circumvention
although success is chemotype dependent upon the net effects of
compound-transporter binding site afﬁnity, passive diffusion rate,
and concentration of compound at the binding site.16
Comparing the data from these two analyses, it was apparent
that factors such as TPSA (or HBA/HBD counts) affecting P-gp efﬂux
and passive permeability also appeared to impact overall unbound
brain exposure. Also, speciﬁcally considering the molecular prop-
erties affecting recognition by P-gp at a global level across the large
set of structurally-diverse compounds, contribution of HBA count
also was aligned with the recent data from Blatter and Seeling.17
They conducted a systematic study of polyoxyethylene alkyl ethers
that varied in the number of methylene and ethoxyl residues as
model P-gp substrates. This study offered better understanding of
the hydrophobic and electrostatic contributions to the process of
substrate binding from water to P-gp within the lipid membrane
environment. The lipid-water partitioning step preceding substratebinding to the P-gp cavity appeared to be driven by hydrophobic
interactions whereas binding from the lipid membrane to the P-
gp cavity seemed to be primarily driven exclusively by H-bonding,
or speciﬁcally HBA.
Whilemost publicationsdescribing keyphysicochemical proper-
ties impacting passive permeability and P-gp substrate recognition
have focused on HBD and HBA counts and TPSA, relatively limited
attention has been paid to detailed understanding of how differ-
ences in the HBD and HBA strengths contribute to these key param-
eters impacting CNS exposure. Thus, for a chemical series where the
total counts of H-bonds and TPSA remain constant while observing
signiﬁcant changes in their P-gp recognition and/or permeability,
it might be valuable to consider H-bond strength as potential
descriptor affecting the outcome. Insights from this analysis then
can be applied to guide structural changes that decrease or over-
come P-gp efﬂux and/or increase passive permeability. Some case
studies from the literature that exemplify this approach are de-
scribed in this review. The reader is referred to additional recent
examples where increased CNS exposure was achieved by reducing
P-gp efﬂux efﬁciency18–20 or where CNS exposure was decreased by
decreasing passive diffusion or increasing P-gp efﬂux efﬁciency.21,22Hydrogen bond strength and impact on p-gp and passive
permeability
H-bond interactions between a ligand and its target protein are
known to play a critical role in determining the overall afﬁnity be-
tween the two. Not surprisingly, such interactions also have been
considered to signiﬁcantly inﬂuence recognition of compounds as
substrates by P-gp.13,16,23 In many cases, especially when compar-
ing different chemical series to each other, a count of the number
of HBD and HBA groups or calculated TPSA may serve as simple
tools to differentiate scaffolds for relative likelihood of P-gp recog-
nition. However, a more rigorous approach also can be desirable
for the description of molecules as has been advocated by Abraham
et al.24 Not all donors and acceptors are ‘equal’ in terms of the
strength of the H-bond that they form with the corresponding
partner and hence parameters that can differentiate or rank order
relative H-bond strengths are valuable. Among some of the exper-
imental sources of H-bond scales, measurement of the H-bond
equilibrium constants of a diverse set of proton donors and accep-
tors by Morris et al. is considered to provide an important refer-
ence set.25 In this approach, 4-nitrophenol was employed as the
standard donor and N-methylpyrrolidinone as the acceptor in pres-
ence of 1,1,1-trichloroethane as solvent with high dipolarity
(e = 7.53; making it a better model than tetrachloro methane/tetra-
chloro ethane for simulating biological membranes). Moreover,
this data set provided good coverage of common HBD/HBA groups
including several heterocyclic compounds. The HBD and HBA
strengths were reported in terms of logKa and logKb values,
‘respectively’. The acidity ‘logKa’ term for a given functional group
relates to the strength of H-bond formed by the solute donor when
it interacts with lone pairs of acceptor groups in solvent molecules.
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bond formed by the lone pairs of an acceptor (the solute) when
it interacts with donor solvents.26 Using such information, it is
now possible to predict the relative strengths of individual
H-bonds, or dipole–dipole attractions, and thus to quantify the
various intermolecular forces between a drug molecule and its
surrounding solvent molecules and/or receptors.
Several authors have reported surrogate in silico methods to
calculate Abraham’s H-bond strength parameters to enable use of
these parameters as descriptors for SAR analysis. Japertas et al.27
reported a fragment-based method while a more rigorous method
based on quantum mechanics calculations has been described by
Gancia et al.28 The latter method was based on the premise that
Abraham’s H-bond scales could be related to parameters derivable
from quantum-mechanical calculations such as atom self-polariz-
ability and electrophilic superdelocalizability. These are, broadly
speaking, parameters that include terms relating to the degree to
which a given molecular orbital receives a contribution from an
atomic orbital, and the energy of the orbital. The calculations were
performed using semi-empirical quantum mechanics methods
such as Austin Model 1 (AM1) 29 or Parametrization Method 3
(PM3).30 In some of the examples described in this review, we have
used logKa and logKb values (as HBD/HBA strengths) calculated
using an internal implementation of the quantum mechanical ap-
proach described by Gancia et al.28
An example of a systematic assessment of HBD/HBA strength of
a larger set of diverse compounds is the classiﬁcation analysis of P-
gp substrates by Didziapetris et al.31 The authors used a fragment-
based approach27 to calculate Abraham’s HBD/HBA strength
parameters, a and b, ‘respectively’.25 The authors compiled a data
set of 1000 compounds from various sources and based on careful
assessment classiﬁed the same into P-gp substrates and non-sub-
strates. The overall analysis highlighted HBA strength based on
Abraham’s b parameter (a measure of HBA strength) as one of
the key descriptors, along with other physicochemical parameters
such as MW, molecular volume, and ionization constants. Three
different types of models were reported—global, probabilistic and
class-speciﬁc. The global model suggested that simple, conforma-
tion-independent properties listed above could be used as indica-
tors to assess the likelihood for a compound to be a P-gp
substrate. Based on this model, compounds with Abraham’s
b > 1.7, MW > 400 and most acidic pKa > 4 are likely to be P-gp sub-
strates while those with b < 1.7, MW < 400 and most basic pKa < 8
are likely to be non-substrates. Abraham’s b parameter was also re-
ported as one of the key descriptors for the probabilistic model
along with volume and indicator variables for acidic or basic nature
of the compounds.
In an interesting case study of voltage-gated calcium channel
inhibitors for the potential treatment of neuropathic pain, an ami-
no-substituted pyrazolopyridazine 1 (Table 1) was identiﬁed as the
key starting point; however, it suffered from high clearance in
rats.32 In an attempt to reduce the clearance, the authors designed
and synthesized compounds with lower hydrophobicity through
the introduction of polar functional groups, exempliﬁed by 2–4
(Table 1). They realized that while 1 was not a P-gp substrate,
inclusion of additional donors/acceptors such as hydroxyl and pri-
mary amine groups, led to recognition by P-gp. The authors then
employed an in-house in silico ‘global’ model for P-gp substrate
recognition that was based on Abraham’s descriptors for HBD/
HBA strengths, total charge, c logD at pH 7.4 and c logP. The model
correctly identiﬁed the P-gp liability for 2–4 and indicated low
probability for 1 to be a P-gp substrate. While using this model
prospectively to mitigate P-gp substrate recognition, the authors
designed and synthesized methoxy derivatives 5 and 6, predicted
to be marginal P-gp substrates, which were later conﬁrmed to have
lower P-gp efﬂux ratios (<2). Further optimization of this series ledto 7 having a balanced proﬁle with desirable potency and ADME
characteristics, including lack of recognition by P-gp. In fact, both
7 and a very close analog 8, showed improved in vivo Kp,brain val-
ues exceeding 0.9 (Kp,brain refers to brain:blood ratio) compared
to 2with Kp,brain value of 0.17. Compounds 7 and 8 also exhibited
desirable activity in the in vivo pain model. Thus, the authors suc-
cessfully utilized an in silico model incorporating HBD/HBA
strengths (along with other descriptors) to guide the SAR to over-
come P-gp liability and identiﬁed compounds with greater total
CNS exposure in vivo.
The next set of examples were selected to illustrate the poten-
tial role of HBD/HBA strengths in driving P-gp recognition within a
highly homologous series where the ‘traditional’ physicochemical
parameters such as HBD/HBA count or calculated TPSA remain
constant. The ﬁrst set of compounds are from the biphenylamino-
cyclopropane carboxamide series reported by Kuduk et al. as part
of their effort to identify potent bradykinin B1 receptor antagonists
with good pharmacokinetic properties including sufﬁcient CNS
exposure for efﬁcacy.33 As shown in Table 2, 9a–d, which only dif-
fer in the R groups attached to the terminal amide, were found to
have similar potency against B1 receptor and acceptable passive
permeability while exhibiting a range of efﬂux ratios (1.4–8.6) by
human P-gp. The dramatic effect of the polyhaloacetamide on P-
gp transport cannot be explained based on the HBD/HBA counts
or TPSA since these values are constant across these compounds.
The authors proposed that the halogens alpha to the amide group
result in a strong electron withdrawing effect thereby making the
amide a poorer HBA that consequently make it less prone to recog-
nition by P-gp. This hypothesis is also supported by our analysis of
the HBD/HBA strengths calculated using the abovementioned
quantum mechanical method (Table 2). The HBA strength of the
terminal amide appears to increase from 1.3 to 2.1 (about 10-fold
increase given that these values are in log scale) as the number of
halogens attached to the amide are gradually removed from 9a–d.
The authors made additional minor structural changes to 9b given
its very poor bioavailability in dog and monkey. Thus, 10was iden-
tiﬁed that maintained the triﬂuoroacetamide group with minimal
P-gp efﬂux, acceptable CNS exposure in accord with receptor occu-
pancy, along with higher bioavailability and lower clearance in
both species.
H-bonding is known to be an important parameter for describ-
ing drug permeability34–36 H-bonding of the solute with water pre-
dominates over H-bonds involving polar atoms of the phospholipid
head groups, which is consistent with the number of water mole-
cules present in this membrane region exceeding the number of li-
pid molecules.37 However, the degree to which a compound
interacts with the solvent water phase is not simply determined
by the total number of H-bonds it is able to form with water mol-
ecules, but by the relative strength of these H-bonds.38 The size
and nature of the non-polar portion of a molecule, which depend
upon the conformation assumed in that region of the membrane,
also has a signiﬁcant inﬂuence on the strength of the H-bonds
the molecule is able to form.37,38 During transmembrane diffusion,
movement of the solute from the region of minimum free energy
(at 15 Å from the bilayer center) into the ordered chain region
within the bilayer interior is energetically disfavored and this is
largely due to the progressive breakage of H-bonds.37 This concept
of desolvation originally proposed by Stein39 was reintroduced by
Burton’s laboratory in the early 1990s with the demonstration that
passive diffusion of a congener series of purposefully designed,
small neutral peptides correlated with the number of H-bond
groups.40 As the number of solute-solvent H-bonds increased, per-
meability decreased and removal of the peptide bonds by N-meth-
ylation resulted in predictable increases in permeability.41,42 As
described in the case of P-gp, and also true for permeability,
consideration of the HBD/HBA strength would be critical when
Table 1
Summary of potency and P-glycoprotein data for compound examples from Myatt et al.32
N
N O
N
N
R
N
N
N
N
N
O
R
R
1, 2 - 6 7 - 8
1
2
3
Compound R1 R2 R3 a2d1 IC50 (nM) Predicted P-gp scorea P-gp Efﬂux ratiob
1 N — — 2 0.38 1.4
2
N
OH
— — 32 0.40 9.1
3
N
NH2
— — 2 0.68 29
4
N
OH
— — 5 0.36 9
5
N
OMe
— — 6 0.01 1.8
6
N
OMe
— — 5 0.03 1.8
7 — OCF3 Cl 8 NA Non-substrate
8 — F OEt 8 NA Non-substrate
a P-gp score calculated by an unpublished Pﬁzer method used by the authors: <0.20 predicts a substrate with high conﬁdence; 0.20–0.00 predicts a borderline
substrate; 0.00–0.20 predicts a borderline non-substrate and >0.20 predicts a non-substrate with high conﬁdence.
b Bi-directional transport ratio of Papp (B–A)/(A–B) across MDCK-MDR1 cell monolayer overexpressing human P-gp.
P. V. Desai et al. / Bioorg. Med. Chem. Lett. 22 (2012) 6540–6548 6543the total number of HBD/HBA are constant across a series of
homologous compounds. In the subsequent text, we provide a
few examples where changes in H-bond strength can explain
changes in passive diffusion of matched pairs.
The ﬁrst example compares compounds 11 and 12 from Cox
et al.43 These dihydropyrrole inhibitors of Kinesin Spindle Protein
were optimized to circumvent P-gp efﬂux (see also44,45). In this
matched pair, a-diﬂuoromethyl substitution on the C2-aminopro-
pyl side chain not only decreased apparent P-gp efﬂux, but also
increased passive permeability nearly 10-fold (Table 3). b-ﬂuorina-
tion reduced the pKa of the amine from 10.3 to 7.0 and increased
logP from 1.2 to 3.2, which are consistent with the increase in
passive diffusion. In this case, neither the number of H-bonds northe TPSA changed at all; however, the predicted HBA strength of
the amine decreased by 6.9-fold for 12 versus 11 (Table 3). The
change in HB accepting strength also is consistent with the change
in passive permeability. It is expected that these H-bond effects
will be less useful in cases for ionic species where electrostatic
interactions may dominate.40
The second example involves piperidine-based renin inhibitors
that were optimized for faster passive diffusion to improve oral
absorption.46 Bi-directional transport in LLC-PK1 cells with and
without rat P-gp expression showed the pyridone series to have
slow (<30 nm/sec) permeability that agreed with poor rat oral bio-
availability (Table 4). It was established that intestinal P-gp also
contributed to low rat oral bioavailability by measuring a 10-fold
Table 2
Summary of potency, passive permeability, P-glycoprotein efﬂux and calculated H-bond accepting strength for selected compounds from Kuduk et al.33
NH
N
H
R
O
O
F
F
O
O O
O
Cl
F
NH
O
N
H
O
CF3
9a-d 10
1
Compounda R hB1Kib (nM) P-gp Efﬂux ratioc HBA (log) Strength of atom 1d Pappe (nm/sec)
9a CF2CF3 1.6 1.4 1.35 310
9b CF3 0.57 2.3 1.39 280
9c CHF2 0.4 3.2 1.63 310
9d CH3 0.93 8.6 2.12 210
10 — 0.44 1.9 1.39 340
a HBD/HBA count and calculated PSA are 2, 6 and 84.5, respectively for all compounds.
b Bradykinin B1 receptor binding afﬁnity.
c Bi-directional transport ratio of Papp (B–A)/(A–B) across MDCK-MDR1 cell monolayer overexpressing human P-gp.
d HBA strength was calculated based on method described in the manuscript.28
e Passive apparent permeability coefﬁcient with P-gp inhibited.
Table 3
Summary of physicochemical values, passive permeability, P-glycoprotein efﬂux and
calculated H-bond accepting strength for two compounds from Cox et al.43
N
NO
FF NH2
N
O N
FF NH2
F
F
1211
1
Compound 11 12
Ppassive
a, nm/sec 40 380
MDR ratiob 1200 5
P-gp efﬂux ratioc 18.5 2.5
logP 1.2 3.2
pKa 10.3 7.0
PSA 46 42
No. of HBA 1 1
No. of HBD 4 4
HBA (log) Strength of amined (atom 1) 2.82 1.98
a Passive apparent permeability coefﬁcient with P-gp inhibited.
b Ratio of cell uptake between parent cell line and cell line over-expressing P-gp.
c Bi-directional transport ratio of Papp (B–A)/(A–B) across MDCK-MDR1 cell
monolayer overexpressing human P-gp.
d HBA strength was calculated based on method described in the manuscript.28
Table 4
Summary of physicochemical values, passive permeability, oral bioavailability and
calculated H-bond accepting strength for two compounds from Levesque et al.46
N
H
N O
O
N
O
Cl
N
O
ClO
N
H
F
F
HO
13
Domain A
14
Compound 13 14
Ppassive
a, nm/sec 10 110
%F, pob 1 16
logD 1.0 3.1
PSA 66 58
No. of HBA 6 5
No. of HBD 1 2
HBA (log) Strength domain Ac 4.92 3.63
HBA (log) Strength totalc 9.24 8.16
a Passive apparent permeability coefﬁcient across LLC-PK1 cell monolayers
without rat P-gp expression.
b Rat bioavailability after oral dose.
c HBA strength was calculated based on method described in the manuscript.28
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with the P-gp inhibitor elacridar (GF120918). They determined
that substitution of the pyridone moiety at the 4-position of the
piperidine ring with a (3,4-diﬂuorophenyl)-piperidin-4-ol aryl
group increased passive permeability, which led to improved oral
absorption by overwhelming gut P-gp efﬂux. They concluded that
the increase in rat oral bioavailability was likely caused by in-
creased passive permeability since there was minimal effect on
P-gp efﬂux. Compound 14 had 11-fold faster passive permeability
than 13, which corresponds to an increase in hydrophobicity, but a
decrease in number of HBA and an increase in the number of HBD.
The modest decrease in PSA from 66 to 58 does not explain morethan 10-fold increase in passive permeability (Table 4). However,
considering the calculated H-bond strengths, it appears that elim-
inating the pyridine and introducing the hydroxyl resulted in a 12-
fold decrease in total HBA strength with only a modest increase in
HBD strength, which is more in line with the extent of increase in
passive permeability (Table 4). This example once again supports
the use of predicted H-bond strength to help drive SAR.
In summary, it appears that when considering a more diverse
set of compounds (‘global data’), the HBD/HBA strength-related
parameters have been identiﬁed as key descriptors, but would
require additional physicochemical parameters to provide a
reasonable indication for P-gp liability across the larger set. On
Table 5
Example of an intramolecular H-bond decreasing P-glycoprotein transport from Kobayashi et al.53
N
H
N
Cl
N
N S
N
H
O
O
CH3
CH3
Cl
N
N
N
CH3
N
H O
CH3
O
O
N
H
R
Cl
N
N
OH
R
CH3
15 16
Compound Linker ORL1 binding IC50 (nM) MW cLog Pa Basic cpKa of benzimidazole Na PSA No. of HBA No. of HBD P-gp efﬂux ratiob
15 S 2.4 466 4.2 4.64 74 7 2 16
16 C@O 5.7 462 3.7 3.55 90 8 2 (1)c 1.9
a Calculated using Chemaxon.
b Bi-directional transport ratio (B/A)/(A/B) across MDCK-MDR1 cell monolayers over-expressing human P-gp.
c The intramolecular H-bond can neutralize the benzimidazole NH, effectively leaving only one HBD as well as masking the additional carbonyl acceptor.
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gous series where the HBD/HBA strength appears to have direct
impact on recognition by P-gp and passive permeability. Various
in silico tools to calculate logKa and logKb provide a reasonable
estimation of the relative HBD/HBA strengths. At the same time,
it should be noted that most tools to calculate these parameters
would face some limitations in handling tautomers and conforma-
tional ﬂexibility. In such cases, care should be taken to ensure that
the most relevant tautomer/conformation is used for calculations.
Also, steric effect or accessibility of the donor/acceptors may not
be differentiated by these methods. Thus, these descriptors may
have limited application when comparing compounds spanning a
range of structural diversity.
Intramolecular hydrogen bonds and impact on P-gp substrate
recognition and passive permeability
An attractive alternative to the permanent removal of HBD, to
maintain target activity, is the introduction of a complementary
HBA that is able to assume a conformation where the two
groups can adopt a suitable geometry and distance to form a
temporary ring or conformation where an intramolecular H-bond
is formed. This temporary ring is different than the intermolecu-
lar conformations with solvent resulting in a thermodynamic
equilibrium between the closed (intramolecular H-bond) and
open (intermolecular H-bond) conformation. Intramolecular H-
bonds, though often weaker than their intermolecular counter-
parts, have signiﬁcant inﬂuence on properties such as charge dis-
tribution within molecules, the relative stability of conformers,
and reactivity.47 The closed form, masking polarity from the
environment and effectively removing one donor and one accep-
tor atom from the molecule, may then be less recognized as a P-
gp substrate. Additionally, the closed form tends to be more
lipophilic and might display faster membrane permeability.48,49
Indeed, Wright and Painter used uptake into red blood cells as
a surrogate for membrane permeability to show that introduc-
tion of an intramolecular H-bond increased permeability of posi-
tional isomers of hydroxybenzoic acid.50
Kuhn et al. reported a systematic analysis of the Cambridge
Crystallographic Database in terms of propensity for intramolecu-
lar H-bond formation of ﬁve- to eight-membered ring systems.49The highest frequency of intramolecular H-bonds was observed
for planar, six-membered rings stabilized by conjugation with a
p-system. Infantes et al. investigated the competition between in-
ter- and intramolecular H-bonding and concluded that intramolec-
ular H-bonds are preferred when ﬁve- or six-membered
conjugated rings are formed.51 A variety of far less-explored topol-
ogies were identiﬁed by Kuhn et al., such as six-membered ring H-
bonds containing one sp3 center (non-planar) and a number of
non-planar, seven- and eight-membered rings.49 They also synthe-
sized a series of closely-related compounds where the changes in
membrane permeability, water solubility and hydrophobicity were
directly related to the potential to form an intramolecular H-bond.
In this section, we will highlight a few recent examples showing
how the formation of an intramolecular H-bond can reduce P-gp
efﬂux and improve target exposure, such as in the brain. The reader
is referred to the decade-old paper by Ashwood et al., which ele-
gantly demonstrates how introduction of an intramolecular H-
bond in the SAR was used to effectively increase CNS exposure.52
To evaluate the biological role of the opioid-related (ORL1)
receptor and assess the therapeutic potential of the ORL1 antago-
nists, it was important to develop orally bioavailable and brain pe-
netrant compounds.53 An initial medicinal chemistry effort by the
Tsukuba researchers led to identiﬁcation of potent and highly-
selective ORL1 antagonists represented by 15 (Table 5). Further
testing revealed that most compounds with a hydrophilic group
on a thioether moiety (like 15) exhibited markedly low brain expo-
sure. They demonstrated that 15 was a substrate for human P-gp,
so SAR was directed to overcome P-gp substrate recognition to in-
crease brain exposure. As part of a systematic SAR, substitution of
the thioether linkage by a ketone (16) was tolerated in terms of
binding afﬁnity in contrast to replacement with methylene, a
nitrogen atom, or an oxygen atom that resulted in complete loss
of potency (Table 5). Interestingly, 16 was not a P-gp substrate.
To explain this unexpected result, the authors speculated that it
might correlate with the decrease in the calculated pKa value of
the benzimidazole. However, an alternative explanation might be
the possibility of intramolecular H-bond formation between the
introduced carbonyl and the benzimidazole NH. Analogous to the
strategy described by Kuhn et al.,49 we conducted a systematic
analysis of relative energies, which were calculated using quantum
mechanical calculations, of open and closed conformations of 16 in
Table 6
Example of an intramolecular H-bond decreasing P-glycoprotein transport from Raﬁ et al.54
O O
N
NH2
O
N
H H
N
N
O
NH2
OO
17 18
Compound MW cLogPa PSA No. of HBD cpKaa A–B Pappb (nm/sec) P-gp efﬂux ratioc
17 299 1.2 94 2 (1d) 4.5 177 1.1
18 299 1.2 94 2 5.1 43 3.1
a Calculated using Chemaxon.
b Apparent permeability coefﬁcient across MDCK-MDR1 cell monolayers in the A-to-B direction.
c Bi-directional transport ratio (B/A)/(A/B) across MDCK-MDR1 cell monolayers overexpressing human P-gp.
d The intramolecular H-bond can effectively neutralize one donor (carbamate NH) and one acceptor (pyridyl N).
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environments, the closed conformation with an intramolecular
H-bond between the carbonyl oxygen and the benzimidazole NH
would be signiﬁcantly more stable than the open form without
such interactions. One can hypothesize that this is likely to result
in loss of potential key interaction between the benzimidazole
NH and P-gp resulting in a signiﬁcant decrease in P-gp substrate
recognition.
To systematically explore the impact of intramolecular H-bonds
on passive permeability, Jacobsen and colleagues have been
designing and synthesizing short peptides and peptidic small mol-
ecules in which a HBA is positioned within proximity of backbone
NH groups.54,55 Matched pairs of compounds containing either
HBA-bearing or unmodiﬁed amino acids were tested for perme-
ability by employing MDR1-MDCK cell monolayers expressing hu-
man P-gp. In the particular pair of compounds shown in Table 6
(17 and 18), the 2-pyridyl analogue (17) was both predicted and
found experimentally to be more permeable than 18 (177 versus
43 nm/sec, respectively).54 The ability of 17 to form an intramolec-
ular H-bond reduced the number of exposed HBD and attenuated
the pKa resulting in increased permeability. There also was a reduc-
tion, albeit modest, in the P-gp efﬂux ratio although this cannot be
attributed directly to a decrease in compound-P-gp interaction (Ta-
ble 6). This study shows that robust conformational analysis, such
as an all-atom force-ﬁeld based method, is a key component of
their analysis making it suitable for intramolecular H-bonding pre-
dictions to optimally reﬁne drug-like properties within a congener
series.
The utility of using intramolecular H-bonds to increase perme-
ability also is nicely captured by a congener series of tripeptidic
neurokinin-2 (NK2) receptor antagonists.56 The N-terminal amide
proton is masked by terminally capping two similar scaffolds with
ortho-substituted heteroatoms capable of forming an intramolecu-
lar H-bond. Membrane permeability was measured in vitro using
both a Parallel Artiﬁcial Membrane Permeability Assay (PAMPA)
and Caco-2 cell monolayers (Table 7). Compound 19 of scaffold A
had very slow permeability. Aromatic chlorine (20) is generally
known to be a poor HBA, but a study by Huque et al. demonstrated
that it decreases the HBD capability of its partner when involved in
an intramolecular interaction. Similarly, ﬂuorine’s role as a HBA is
also debated.57 A ﬂuorine atom bonded to carbon needs very short
contacts (2.6 Å) with acidic hydrogen atoms in order to act as a
HBA, so this distance criterion is not reliable to infer F  H H-bond
formation.58,59 But, aromatic ﬂuorine as in 21 can participate in
signiﬁcant H-bonds albeit weaker than those involving HBAs such
as oxygen and nitrogen.60 Both halogenated compounds increased
permeability in both assays with ﬂuorine yielding the greatereffect (Table 7). A similar, but more dramatic, effect was achieved
in scaffolds A and B using ortho pyridine (23 vs 22) and isoquino-
line (25 vs 24) (Table 7). Isoquinoline 25 proved the most shielded
in DMSO and water, as determined by NMR studies on temperature
dependence of the NH resonance value, which agrees with the per-
meability data.
Labby et al. introduced an intramolecular H-bond within selec-
tive syn-3,4-substituted pyrrolidine inhibitors of neuronal nitric
oxide synthase (nNOS) to increase their membrane permeability
for improved oral and blood–brain barrier absorption (Fig. 2).61
They had tried different strategies like replacing the high pKa ami-
no groups with neutral functionalities such as ethers and amides or
by inserting electron-withdrawing groups, such as ether, monoﬂu-
oromethylene, diﬂuoromethylene, and cyclopropyl, to inductively
decrease the pKa of the amino group, but despite improved mem-
brane permeability, in vitro potency and selectivity were adversely
compromised. Compounds 26a–c have benzyl-like aryl substitu-
ents so that 6-membered intramolecular H-bonds would form.
The 5-membered intramolecular HB (26d) was found to be the
least likely to form, which is consistent with Kuhn et al.49 Using
NMR spectroscopy, H-bonding was observed in water at physiolog-
ical pH and above 37 C suggesting that the intramolecular H-
bonds of 26b and 26c are stable in solution and that this approach
would be amenable to enhancing membrane permeability in vivo.
Interestingly, they found, using an indirect in vitro measure to rep-
resent relative permeability, 26a and 26b had the highest perme-
ability despite NMR evidence that compounds 26b and 26c
formed an intramolecular H-bond. In spite of the dogma that ﬂuo-
rine-mediated H-bonds are weak, the results with 26a were incon-
sistent with this interpretation and contrary to the NMR evidence
provided. The authors suggested that 26a with a ﬂuorophenyl has
higher lipophilicity plus ﬂuorine decreased the pka of the basic
nitrogen, where as 26c has polar hydroxyl group. It is known that
a single, aromatic H/F exchange raises logD by 0.25 and larger in-
creases in logD are usually seen when ﬂuorine is introduced near-
by a basic N increasing the ratio of neutral to protonated
molecules.62 These F  H–N intramolecular H-bonds or dipolar
interactions could be made stronger depending upon the func-
tional group in the beta position with respect to the F atom to ef-
fect its shielding.63
The above-mentioned examples clearly highlight the potential
impact of introducing an intramolecular H-bond to address P-gp
efﬂux and/or passive permeability. It should be noted that when
designing compounds to incorporate intramolecular H-bonds, the
arrangement of donor–acceptor pair in a suitable location may
not be a sufﬁcient indicator that such interactions will occur. As
described in detail elsewhere, it is critical to consider relative
Table 7
Example of an intramolecular H-bond increasing passive permeability56
N
H
N
H
N
H N
O
O
O
O O
N
H O
N
H
N
N
O
N
X
Y N
Ar
A
Ar = 
Bu
19,  X = H
20,  X = Cl
21,  X = F
22,  Y = CH
23,  Y = N
24 25
Ar = 
Ar
B
Compound 19 20 21 22 23 24 25
PAMPAa (nm/sec) — 1.6 6.6 16 72 60 155
Caco-2b (nm/sec) <10 42 138 93 176 146 252
a Apparent permeability coefﬁcient from the Parallel Artiﬁcial Membrane Permeability Assay (PAMPA).
b Permeability across Caco-2 cell monolayers.
N
H
O
N
H
X
N
NH2
H
H
N
F
H H
N
O
N
O
H
H
H
N
O
26a-d
26a 26b 26c 26d
+
+
Figure 2. Impact of different intramolecular H-bonds to increase membrane
permeability.61
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in both water and the membrane environment, and the impact of
intramolecular H-bond formation on changes in the free energy
associated with transfer of the compound from water to mem-
brane or to P-gp within the membrane.49,54,61,63 It is also important
to consider how the intramolecular H-bond might impact other
attributes beyond intrinsic activity such as solubility. If solubility
is affected negatively, such as in a difference in crystal packing,
then dissolution rate in the GI tract could decrease and result in
lower oral bioavailability.64
In summary, the balancing of multiple key attributes during
optimization of a chemical series can be challenging and is some-
times under-supported, or even misled, by application of a handful
of easily computed molecular properties that broadly describe glo-
bal characteristics and trends. The requirement to cross a biologi-
cal membrane can be a complex process especially if ABC
multidrug transporters such as P-gp must be considered. For exam-
ple, use of a popular PSA descriptor alone accounts for only 50–60%
of total absorption variance65 despite its undeniable impact on
medicinal chemistry.66 Drug partitioning into the lipid membrane
and drug binding to P-gp within the lipid membrane are tightly
coupled processes where too many H-bonding groups in a drug
molecule can have a deleterious effect on membrane penetration,
due to energetically unfavorable water desolvation and bindingof a drug molecule to P-gp is favored primarily through H-bond
accepting groups. Using a number of examples from the recent lit-
erature, we have illustrated the beneﬁts of predicting the relative
strengths of individual H-bonds and introducing intramolecular
H-bonds to increase membrane permeability and/or decrease P-
gp transport. Despite potential ramiﬁcations for potency, removal
of H-bonding groups is a muchmore effective and efﬁcient strategy
than adding more hydrocarbon and, in lieu of permanently remov-
ing H-bonds to maintain target activity, introduction of a intramo-
lecular H-bond to mask groups that are required for potency may
be the preferred strategy to achieve improved target engagement.
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